ASTELLAS PHARMA
- Country
- ๐ฏ๐ตJapan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
- Conditions
- SCLCCarcinoma, Small Cell
- First Posted Date
- 2002-10-04
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 47
- Registration Number
- NCT00046787
- Locations
- ๐ฌ๐ง
Christie Hospital, Manchester, United Kingdom
๐บ๐ธVanderbilt Clinical Trials Office, Nashville, Tennessee, United States
๐บ๐ธUniversity of Colorado Health Sciences Center, Denver, Colorado, United States
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
- Conditions
- Cerebrovascular Accident
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2006-04-03
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00044070
- Locations
- ๐บ๐ธ
Holmes Regional Medical Center, Melbourne, Florida, United States
๐บ๐ธJohns Hopkins Medical Institute, Baltimore, Maryland, United States
๐บ๐ธUniversity of Pittsburgh Medical Center Stroke Institute, Pittsburgh, Pennsylvania, United States
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2006-04-03
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00044057
- Locations
- ๐บ๐ธ
University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
๐บ๐ธUniversity of Maryland Medical System, Baltimore, Maryland, United States
๐ง๐ชDienst Neurologie UZ Gasthuisberg, Leuven, Belgium
CP-461 for the Treatment of Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2002-07-24
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00042055
- Locations
- ๐บ๐ธ
Southern Drug Research, Birmingham, Alabama, United States
๐บ๐ธFlorida Medical Research Institute, PA, Gainesville, Florida, United States
๐บ๐ธUniversity of Chicago Medical Center, Chicago, Illinois, United States
Study of FK463 for the Treatment of Invasive Aspergillosis
- Conditions
- Aspergillosis
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 326
- Registration Number
- NCT00036166
- Locations
- ๐ซ๐ท
Hopital Henri Mondor, Service d'Hematologie Clinique, Creteil, France
๐ซ๐ทHotel Dieu, Service d'Hematologie, Nantes, France
๐ซ๐ทHopital Saint Louis, Service D'Hematologie/Greffe de Moelle, Paris, France
Study to Assess Efficacy of Tacrolimus + Methotrexate Versus Placebo + Methotrexate in Treatment of Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 210
- Registration Number
- NCT00036153
- Locations
- ๐บ๐ธ
Arthritis & Rheumatology Associates of Palm Beach, West Palm Beach, Florida, United States
๐บ๐ธRadiant Research - Dallas, Dallas, Texas, United States
๐บ๐ธRheumatology Associates of North Alabama, Huntsville, Alabama, United States
Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2011-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00036192
- Locations
- ๐บ๐ธ
Clireco, Inc., Tamarac, Florida, United States
๐บ๐ธRadiant Research - Minneapolis, Edina, Minnesota, United States
๐บ๐ธInternational Institute of Clinical Research, Inc., Ozark, Alabama, United States
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 15
- Registration Number
- NCT00036257
- Locations
- ๐บ๐ธ
Albany Regional Cancer Center, Albany, New York, United States
๐บ๐ธCancer Care Northwest, Spokane, Washington, United States
๐บ๐ธTyler Cancer Center, Tyler, Texas, United States
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
- Conditions
- Candidiasis
- First Posted Date
- 2002-05-09
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT00036179
- Locations
- ๐ซ๐ท
Hopital Henri Mondor, Dervice d'Hematologie Clinique, Creteil, France
๐ฉ๐ชKlinikum der Stadt, Medizinische Klinik A, Ludwigshafen, Germany
๐ฉ๐ชUniversitat Wurzburg, Institut fur Molekulare und Infectionsbiologie, Wurzburg, Germany
Study of CP-461 in Patients With Advanced Renal Cell Cancer
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 14
- Registration Number
- NCT00036036
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States